Search the Newsreel

RXST Lowered by UBS - Price Target Reduced to $5.50

UBS has lowered its price target for RxSight Inc (RXST) from $9.00 to $5.50, maintaining a 'Neutral' rating, reflecting a cautious outlook despite the company being deemed 83.4% undervalued by GuruFocus's GF Value. RxSight, which focuses on innovative intraocular lens technology, faces mixed analyst …

UBS Adjusts Price Target on RxSight to $5.50 From $9, Maintains Neutral Rating

UBS has revised its price target for RxSight (RXST) shares downwards to $5.50 from the previous $9, while maintaining a Neutral rating on the stock. The adjustment reflects an updated outlook from the analyst firm. This news follows several recent announcements from RxSight, including …

RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer

RxSight, Inc. (NASDAQ: RXST) has announced a leadership transition effective July 20, 2026, with Aziz Mottiwala taking over as President and Chief Executive Officer. He succeeds Ron Kurtz, M.D., who will continue as Chief Medical Officer. The company believes Mottiwala's extensive commercial leadership experience …

RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

RxSight, Inc. announced incentive grants to its new President and Chief Executive Officer, Aziz Mottiwala. These grants include stock options for 571,286 shares and restricted stock units (RSUs) for 2,312,138 shares, issued on July 24, 2026, and vest over one to three years. The …

Leadership watch: RxSight, Exonate tap new CEOs; CooperVision, Lumenis, and OSU fill top roles

This article details significant leadership changes across several companies and institutions in the eyecare sector. RxSight and Exonate have appointed new CEOs, while CooperVision and Lumenis have filled key executive roles. Additionally, The Ohio State University's College of Optometry announced a new dean, highlighting …

Rxsight Inc (RXST) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the major shareholders and institutional holdings of Rxsight Inc (RXST), providing a breakdown of shareholder types, top shareholders, and institutional shareholding trends over time. Key data points include percentages held by investment advisors, hedge funds, and individual investors, along with quarterly …

RxSight grants inducement stock options and RSU...

RxSight, Inc. granted new President and CEO Aziz Mottiwala inducement stock options for 571,286 shares and restricted stock units (RSUs) for 2,312,138 shares. These grants, effective July 24, 2026, are part of the company's 2026 Inducement Equity Incentive Plan and are designed to incentivize …

Levi & Korsinsky Notifies RxSight, Inc. (RXST) Shareholders of Class Action Lawsuit and September 22, 2025 Deadline

Levi & Korsinsky has announced a class action lawsuit against RxSight, Inc. (NASDAQ:RXST) on behalf of shareholders who suffered losses due to alleged securities fraud between May 7, 2024, and July 8, 2025. The lawsuit claims RxSight made false statements and concealed "adoption challenges" …

RXST|Rxsight Inc|Price:5.205|Chg%:-0.165

This article provides a detailed financial overview of Rxsight Inc. (RXST), including its recent stock performance, financial statements, and key indicators. It highlights the company's Q1 FY2026 earnings forecast with an EPS of -0.35 and revenue of 32.47M, and a current analyst rating of …

Rxsight Inc (RXST) Earnings Forecast: Future EPS & Revenue Growth Estimates

Rxsight Inc (RXST) has an earnings forecast score of 5.80, placing it 185th in the Healthcare Equipment & Supplies industry. Analysts have set an average price target of $10.00 for RXST, with individual forecasts ranging from $8.00 to $14.00, representing a potential upside of …

RxSight (RXST) Stock Fair Value Falls After Soft Q2 Trends And Guidance Cut

Form 4 Rxsight Inc For: 24 July By Investing.com

This article from Investing.com is a regulatory filing notification, specifically a Form 4 for Rxsight Inc. dated July 24. It indicates insider transaction activity for the company, though the details of the transactions are not provided within the snippet. The article also includes market …

RxSight, Inc. (RXST) awards CEO 2,312,138 RSUs and 571,286 options

RxSight, Inc. (RXST) has granted its President and CEO, Aziz Mottiwala, 2,312,138 restricted stock units (RSUs) and options for 571,286 shares with an exercise price of $5.19 per share. These equity awards, reported in a Form 4 SEC filing, are designed to vest over …

BlackRock Portfolio Management (RXST) discloses 7.2% beneficial stake in RxSight

BlackRock Portfolio Management LLC has disclosed a 7.2% beneficial ownership stake in RxSight, Inc. (RXST), holding 2,982,816 shares as of June 30, 2026. The firm maintains sole voting power over 2,618,543 shares and sole dispositive power over all 2,982,816 shares, with no shared powers. …

Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Kazia Therapeutics (KZIA) and Crescent Biopharma (CBIO)

Healthcare companies RxSight (RXST), Kazia Therapeutics (KZIA), and Crescent Biopharma (CBIO) have recently received analyst coverage. BTIG analysts offered ratings for RxSight and Kazia Therapeutics, while H.C. Wainwright provided an update for Crescent Biopharma. The article details analyst ratings, price targets, and consensus views …

RxSight (RXST) Surges 6.1%: Is This an Indication of Further Gains?

RxSight (RXST) shares increased by 6.1% to $5.57, driven by high trading volume and investor optimism regarding an upcoming leadership transition. Aziz Mottiwala is set to become the new President and CEO on July 20, 2026. Despite a projected quarterly loss of $0.21 per …

Alcon (SWX:ALC) After The RxSight Deal Is The Growth Story Already Priced In

Alcon (SWX:ALC) has gained attention after a collaboration with RxSight for adjustable presbyopia-correcting intraocular lenses, leading to recent share price momentum. However, despite a "25.7% Undervalued" narrative targeting a fair value of CHF76.62 due to new product launches and M&A, the current P/E ratio …

RxSight Tags Aziz Mottiwala as President and CEO, Ron Kurtz, MD, as CMO

RxSight, Inc. has announced a leadership transition, appointing Aziz Mottiwala as president and CEO, effective July 20, 2026. Current CEO Ron Kurtz, MD, will transition to chief medical officer and resign from the board of directors, with Mottiwala joining the board. This change follows …

RxSight names Aziz Mottiwala as new CEO effective July 20 By Investing.com

RxSight, Inc. has announced Aziz Mottiwala as its new President and CEO, effective July 20, replacing Ron Kurtz, who will become Chief Medical Officer. This leadership change occurs as RxSight's stock has seen a significant decline, though InvestingPro analysis suggests it may be undervalued. …

RxSight (NASDAQ: RXST) hires new CEO, sets $14M equity package

RxSight, Inc. (NASDAQ: RXST) announced a leadership transition, appointing Aziz Mottiwala as President and CEO, effective July 20, 2026. Former CEO Ron Kurtz, M.D., will transition to Chief Medical Officer. Mottiwala's compensation package includes a $750,000 base salary, guaranteed cash bonus, and $14 million …

RxSight CEO Ron Kurtz to Continue as Chief Medical Officer

RxSight (NASDAQ: RXST) announced a leadership transition effective July 20, 2026, appointing Aziz Mottiwala as President and Chief Executive Officer. Ron Kurtz, M.D., the current CEO, will transition to Chief Medical Officer, focusing on technology and clinical development, and will resign from the Board. …

Press Release: RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer

RxSight has announced significant leadership changes, appointing Aziz Mottiwala as the new Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer, effective immediately. Mr. Mottiwala previously served as Chief Commercial Officer, while Dr. Kurtz was a co-founder and former CEO of the …

Pacific Radiance Ltd.'s (SGX:RXS) most bullish insider, CEO Yoke Min Pang must be pleased with the recent 18% gain

Pacific Radiance Ltd Financial Statements – SGX:RXS